Eli Lilly and Co.'s EXPEDITION3 clinical study involving solanezumab failed to meet its primary goal in treating Alzheimer’s. Read More »

Novo Nordisk's Changing Diabetes in Children program has received a four-year extension to provide access to diabetes care and free insulin to children in developing countries who have Type 1 diabetes. Read More »

Merck has released new data involving KEYTRUDA, Merck’s anti-PD-1 therapy designed for the treatment of a number of blood cancers, and its investigational use. Read More »

Mallinckrodt's Phase 2 clinical study involving H.P. Acthar Gel to evaluate the effectiveness of the medication on patients who have Amytropic Lateral Sclerosis will begin in 2017. Read More »

CVS Pharmacy's Black Friday sales event will give its ExtraCare members the opportunity to save. Read More »

Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program. Read More »

Kmart Pharmacy has added Medicare Part D and its members can now use Kmart Pharmacy for their pharmaceutical needs in 2017 as their preferred provider. Read More »

Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology annual meeting. Read More »

The Academy of Managed Care Pharmacy recently hosted a national health care forum about value and outcomes in oncology where the key topics of conversation revolved around the fast-growing innovations in oncology and how complex cancer treatments have become. Read More »

Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data. Read More »

Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib, which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma. Read More »

Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »

Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »

Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »

Crescendo Biosciences gave four poster presentations showcasing Vectra DA at the American College of Rheumatology meeting in Washington D.C. this week. Read More »

The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »

Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »

Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »

Imprimis Pharmaceuticals has reached a purchase and supply agreement with the specialty pharmacy division of one of the country’s biggest pharmacy benefits managers Read More »